Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
Abstract Background Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety...
Main Authors: | Nan Chen, Changying Xing, Jianying Niu, Bicheng Liu, Junzhou Fu, Jiuyang Zhao, Zhaohui Ni, Mei Wang, Wenhu Liu, Jinghong Zhao, Ling Zhong, Xiongfei Wu, Wenge Li, Yuqing Chen, Wei Shi, Jianghua Chen, Aiping Yin, Ping Fu, Rong Wang, Gengru Jiang, Fanfan Hou, Guohua Ding, Jing Chen, Gang Xu, Yuichiro Kondo, Yuliang Su, Changlin Mei |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-03-01
|
Series: | Chronic Diseases and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cdt3.13 |
Similar Items
-
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
by: Bicheng Liu, et al.
Published: (2022-06-01) -
Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease
by: Prasad Apsangikar, et al.
Published: (2018-01-01) -
Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
by: Shubhadeep D. Sinha, et al.
Published: (2019-03-01) -
USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP
by: Maria Gaydarova, et al.
Published: (2017-01-01) -
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021-04-01)